182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy
| Autor: | Blanch, S., Pérez-García, J.M., Balmaña, J., Prat, A., Alés-Martínez, J.E., de la Haba, J., Alba, E., Palacios-Ozores, P., Ramos, M., Lema, L., García Sáenz, J.Á., Sampayo-Cordero, M., Malfettone, A., Cortés, J., Llombart Cussac, A. |
|---|---|
| Zdroj: | In Annals of Oncology May 2020 31 Supplement 2:S82-S82 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|